An anticancer camera?

Dr. Petra Wilder-Smith’s screening device takes aim at oral lesions

Now, in collaboration with Rongguang Liang at the University of Arizona’s Wyant College of Optical Sciences, the director of dentistry at UC Irvine’s Beckman Laser Institute & Medical Clinic and a professor of surgery has developed a commercial intraoral camera with the ability to screen for cancer.

The current method for oral cancer detection involves a professional looking into the mouth and feeling for lumps. Oral cancer lesions are largely heterogeneous, so they present in many different, easy-to-miss forms. Since treatment is planned around an oral biopsy, it’s best to be able to identify and take a sample from the most dangerous part of the lesion.

“There’s everything from little dots with severe cancer to little dots that are healthy and to little areas that are in between,” Wilder-Smith says. “Just by looking at it, I don’t know where to biopsy, because I can’t tell where the most severe disease is.”

Testing has shown that her and Liang’s intraoral camera will boost the accuracy of oral cancer detection from 40 to 60 percent to 87 to 93 percent. This will change dentistry for end-users, says hygienist Cherie Wink, a researcher at the Beckman Laser Institute and an instructor in San Joaquin Valley College’s dental hygiene program.

“As a clinician,” she says, “this device will eliminate the guesswork in interpreting clinical findings, leading to earlier diagnoses and improved patient outcomes.”

The project, which started in 2008, received funding from the National Cancer Institute and the National Institutes of Health. A patent was recently secured with help from UCI Beall Applied Innovation, which oversees all the campus’s patents and licensing efforts. Alvin Viray, its associate director of licensing, is proud to be part of the project.

“Dr. Wilder-Smith has been nothing short of exceptional,” he says. “Her development of an imaging device for oral cancer detection is both innovative and commercially valuable, while promising to make a profound impact on public health.”

UC Irvine and the University of Arizona own the camera’s patent. While the device has not been licensed yet, Wilder-Smith will soon be seeking a second stage of investors, and Viray is in licensing discussions.

The camera has already seen 10 prototypes. One was smartphone-based and took the form of a phone case that, when connected to an intraoral camera, could image oral lesions. There is currently a final prototype being used for testing and algorithm fine-tuning. The next step is to evaluate it for manufacturing.

In her career at the Beckman Laser Institute, Wilder-Smith has also worked on other devices. She was part of a team that redesigned tools generating aerosol emissions so they would stop spreading aerosol-transmissible illnesses, such as colds and the flu.

Wilder-Smith has also been involved in studies linking topical oral treatments to changes in the microbiome and the gastrointestinal tract, which can have far-reaching consequences for whole-body health. But her main focus now remains on the intraoral camera.

“Quite simply, my goal is to improve oral cancer outcomes,” she says, “because it’s the only major cancer whose outcomes are still getting worse.”

Click here to read full article on UC Irvine News.

Professor Christopher Barty is pushing cancer treatment into the future

The UCI physicist is developing a machine that can find and treat cancer anywhere in the human body.

Imagine a machine that can selectively image cancer in the body and also eliminate that cancer while minimizing damage to any surrounding tissue. It may sound fictional, but Lumitron Technologies, a company housed in the UCI Research Park and co-founded by Professor Christopher Barty of the UC Irvine Department of Physics & Astronomy, is developing a novel X-ray and electron beam machine called HyperVIEW™ that may soon do just that. “The machine has now generated electron beams that can be used to treat cancer anywhere in the human body and X-ray beams that follow the same path as the electrons that can image cancer at 100 times beyond the resolution of conventional clinical systems,” said Barty. “The holy grail is that ultimately you will have the ability to guide your cancer treatment in ways that nobody’s ever been able to do before.” HyperVIEW™ is a fourth-generation, laser-Compton X-ray technology Barty started developing when he was a scientist at Lawrence Livermore National Laboratory.  HyperVIEW™ X-rays will  “allow you to image soft tissues at potentially cellular levels, something that has only ever been done at billion-dollar synchrotron facilities” Barty said, which means Lumitron’s technology could one day both track and treat cancer at the cellular level in the human body. The company plans to have FDA approval for initial, precision cancer imaging applications by late 2025 and will move HyperVIEW™ to pre-clinical cancer treatment studies late this summer. “With this technology, we may eliminate the need to ever remove a breast or prostate again,” said Barty.

Click here to read the full article on the UC Irvine School of Physical Sciences website.